Piper Sandler raised its price target on AbbVie (NYSE: ABBV) to $298 from $294 on May 14, maintaining an Overweight rating. The analyst firm highlighted the company's extensive pipeline for inflammatory bowel disease (IBD) as a primary driver of investor interest. At the 2026 Digestive...
AbbVie reported first-quarter 2024 worldwide net revenues of approximately $12.3 billion, reflecting a strategic transition as its blockbuster immunology drug Humira faces significant erosion from biosimilar competition while newer therapies Skyrizi and Rinvoq drive growth. Management highlighted that Humira sales continued to decline year-over-year, particularly...
AbbVie announced the appointment of Tanu Misra as Vice President and General Manager for its Canadian operations effective May 11, 2026. Misra, who joined AbbVie in 2012, previously served as Vice President of Dermatology, Psoriatic, U.S., Immunology, where she drove growth through commercial strategy and...
AbbVie Inc. (NYSE: ABBV) is presented as a buy opportunity due to strengthening fundamentals and a valuation near multiyear lows following recent underperformance. The article highlights that Q1 net revenues grew 12.4% year-over-year, demonstrating robust business activity even while acknowledging some instability within the Immunology...
AbbVie Inc., headquartered in North Chicago, maintains a substantial market capitalization of $356.4 billion while focusing its development and commercialization efforts on medicines within immunology, oncology, neuroscience, aesthetics, and eye care sectors. Although the stock has trailed the broader S&P 500 over the past year...
